Suggestions
Jim Hollingshead
President and CEO, Insulet Corporation
Jim Hollingshead is the President and CEO of Insulet Corporation, a medical device company renowned for its innovative insulin delivery systems, particularly the Omnipod 5, which is the first and only wearable disposable automated insulin delivery system. He has held this position since June 2022, after serving on the company's board of directors for three years.12
Professional Background
Hollingshead has extensive experience in the healthcare sector. Before joining Insulet, he was with ResMed, where he served as the President of the Sleep & Respiratory Care Division from 2020 to 2022. His tenure at ResMed began in 2010 as the Chief Strategy Officer, where he played a crucial role in accelerating growth and diversifying the business. He has also held various leadership roles at Deloitte Consulting and The Monitor Group, contributing significantly to strategic development and market penetration strategies.123
Education
Hollingshead holds a Bachelor's degree in History and International Relations from Stanford University and both a Master's and PhD in Political Science from the University of California, Berkeley. His academic achievements include being a National Science Foundation Fellow.23
Leadership Philosophy
In his leadership role at Insulet, Hollingshead emphasizes the importance of hiring individuals with "mental agility" who can think broadly and collaborate effectively. He advocates for a culture where team members feel empowered to voice their opinions while working towards common goals.34
Achievements and Recognition
Under Hollingshead's leadership, Insulet has seen significant advancements in diabetes care innovation, including the successful rollout of the Omnipod 5, which has become a leading automated insulin delivery technology in the U.S..4 He has been recognized as one of the top medical device executives in 2019 by The Healthcare Technology Report.2
In summary, Jim Hollingshead combines a robust background in healthcare management with a commitment to innovation and effective leadership at Insulet Corporation.
Highlights
For the more than 30 million Americans with type 2 diabetes, managing their condition is a heavy burden. That is especially true for the roughly 6 million who require insulin therapy. Today, with the FDA clearance of the Omnipod® 5 for type 2 diabetes, millions more people now have access to a simplified diabetes management system that eliminates the need for multiple daily injections and automatically adjusts insulin delivery every five minutes. This marks a pivotal milestone for Omnipod 5, making it the first and only automated insulin delivery system indicated for both type 1 and type 2 diabetes. This clearance was supported by the results of Insulet Corporation’s landmark SECURE-T2D clinical trial, which showed significant glycemic and quality of life improvements with the use of Omnipod 5 compared with prior methods of insulin delivery. Now, our game-changing technology can address a significant unmet need, transforming care, improving clinical outcomes, and simplifying life for people living with type 2 diabetes and those who care about them.
Learn more: https://lnkd.in/gDN8qseu
Last week I traveled to Insulet Corporation’s Australia office and had the opportunity to meet with our team, led by Country Manager Joanna Sader, as well as local health care providers and advocates, all of whom are working to improve the lives of people with diabetes by expanding access to innovative technologies. I also spent time talking with some of our youngest Australian Podders and their families. It was incredible to hear the challenges they’ve faced at such a young age, and immensely gratifying to hear how Pod therapy is making a difference in their diabetes management.
We are thrilled that Insulet’s Omnipod 5 Automated Insulin Delivery System has been approved by Australia’s Therapeutic Goods Administration (TGA). It is an important first step towards making it commercially available to the many Australians (130,000+) with type 1 diabetes.
